Articles

In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

Reaction Biology Acquires Bioassay GmbH for Increasing Large Molecule Capabilities 

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.

Agilent Sets Up Dissolution Testing Hub in UK

Cheryl Barton is director of PharmaVision, 

The European Human Medicines Directive and Regulation is due to be updated by the end of 2022, but what changes are on the cards?

Overhauling the Human Medicines Directive and Regulation 

Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.

The Next Blockbuster

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

mRNA Hauptbahnhof

Mike Hennessy Jr. is the Chairman and CEO of 

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Of Mice and Men and Armadillos

Catalent has completed the expansion of its clinical supply facility located in Shanghai, China. 

Catalent Completes Expansion of Clinical Supply Facility

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

Merck will use BigHat’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs.

Merck and BigHat BioSciences Partner on Drug Discovery Programs 

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.

News